RestorGenex Granted Orphan Drug Designation for RES-529 for Treatment of Glioblastoma Multiforme
January 28, 2015 07:00 ET
|
RestorGenex
BUFFALO GROVE, Ill., Jan. 28, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways
January 23, 2015 07:00 ET
|
RestorGenex
BUFFALO GROVE, Ill., Jan. 23, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and...
RestorGenex Completes Acquisition of Two Biopharmaceutical Companies
April 01, 2014 07:30 ET
|
RestorGenex
LOS ANGELES, April 1, 2014 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:SMDID), announced today the closing of its acquisition of two biopharmaceuticals companies, Paloma Pharmaceuticals, Inc....
RestorGenex Names Stephen M. Simes as Chief Executive Officer
March 10, 2014 07:00 ET
|
RestorGenex
CHICAGO, March 10, 2014 (GLOBE NEWSWIRE) -- RestorGenex (OTCBB:SMDID) announced today that it has named Stephen M. Simes as its Chief Executive Officer, to lead the company. Mr. Simes formerly served...
Stratus Media Group Announces Name Change to RestorGenex and Reverse Split
March 07, 2014 16:00 ET
|
RestorGenex
LOS ANGELES, March 7, 2014 (GLOBE NEWSWIRE) -- Stratus Media Group, Inc., (OTCBB:SMDI) announced today a name change to RestorGenex Corporation (RestorGenex), as well as a 1 for 100 reverse split of...
Stratus Media Group Acquires Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.
March 06, 2014 07:30 ET
|
RestorGenex
LOS ANGELES, March 6, 2014 (GLOBE NEWSWIRE) -- Stratus Media Group, Inc., (OTCBB:SMDI) announced today the acquisition, through merger, of two biotechnology companies, Paloma Pharmaceuticals, Inc. and...